Bobak Azamian
Fortune : 53 M $ au 31/05/2026
Fortune : 53 M $ au 31/05/2026
Bobak Azamian was the founder of Metavention, Inc., founded in 2012, where the title held was President & Chief Medical Officer in 2018.
Dr. Azamian is the founder of Tarsus Pharmaceuticals, Inc., founded in 2017, holding the titles of Chairman, President & Chief Executive Officer since 2022.
Dr. Azamian is the founder of Vibrato Medical, Inc., founded in 2016, serving as Director.
Dr. Azamian is also the founder of Novel Therapeutics Co...
Dr. Azamian currently serves as Director at Osanni Bio, Inc. since 2022.
Former positions include Director at OCTANe, Principal at Amgen, Inc., Principal at Versant Venture Management LLC, and Senior Associate at Third Rock Ventures LLC.
Education includes a doctorate from the University of Oxford, an undergraduate degree from William Marsh Rice University, and a doctorate from Harvard Medical School.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/03/2026 | 891 412 ( 2,07% ) | 53 M $ | 31/05/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| TARSUS PHARMACEUTICALS, INC. | Directeur Général | 01/09/2018 |
Vibrato Medical, Inc.
Vibrato Medical, Inc. Medical SpecialtiesHealth Technology Develops noninvasive treatment for critical limb ischemia and peripheral arterial disease | Fondateur | 01/12/2016 |
| Sociétés | Poste | Fin |
|---|---|---|
Metavention, Inc.
Metavention, Inc. Medical SpecialtiesHealth Technology Develops medical devices for high blood pressure and metabolic diseases | Directeur Général | 01/01/2018 |
Novel Therapeutics Co. | Fondateur | - |
OCTANe
OCTANe Miscellaneous Commercial ServicesCommercial Services Operates an organization helps create, grow, support, staff and fund innovative companies | Directeur/Membre du Conseil | - |
Versant Venture Management LLC
Versant Venture Management LLC Investment ManagersFinance Versant Ventures invests in biotechnology companies located globally. The firm participates in early and later stage capital requirements. | Private Equity Investor | - |
| AMGEN INC. | Corporate Officer/Principal | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 11 |
|---|---|
Amgen, Inc.
Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
University of Oxford
University of Oxford Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Rice University
Rice University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Versant Venture Management LLC
Versant Venture Management LLC Investment ManagersFinance Versant Ventures invests in biotechnology companies located globally. The firm participates in early and later stage capital requirements. | Finance |
Third Rock Ventures LLC
Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures invests in companies located in the United States. The firm targets companies operating in the fields of the healthcare sector. It provides financing for early stage capital requirements. It acts as a lead investor. | Finance |
Harvard Medical School
Harvard Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
OCTANe
OCTANe Miscellaneous Commercial ServicesCommercial Services Operates an organization helps create, grow, support, staff and fund innovative companies | Commercial Services |
Metavention, Inc.
Metavention, Inc. Medical SpecialtiesHealth Technology Develops medical devices for high blood pressure and metabolic diseases | Health Technology |
Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company which develops and commercializes therapeutic drugs for blepharitis | Health Technology |
Vibrato Medical, Inc.
Vibrato Medical, Inc. Medical SpecialtiesHealth Technology Develops noninvasive treatment for critical limb ischemia and peripheral arterial disease | Health Technology |
Novel Therapeutics Co. |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national